Cyclic peptoid oligomers, pharmaceutical compositions and methods of using the same
Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: wherein R 1 and n are as described herein. The peptoids demonstrate antimicrobial and antimalarial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial or malarial infection is involved. The present cyclic peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.
1. A peptoid oligomer according to formula VIIa, VIIb, VIIc, VIIIa, VIIIb or VIIIc:
or a peptoid oligomer according to formula VIIa, VIIb, VIIc, VIIIa, VIIIb or VIIIc, and wherein the —NH 2 of each —CH 2 —CH 2 —CH 2 —NH 2 is replaced with —NMe 2 , —NHMe, or —NEt 2 ;
or a pharmaceutically acceptable salt, or solvate thereof or a stereoisomer, isotopic variant or tautomer thereof.
2. A peptoid oligomer C103, C105, C106, C121, C122, C123, C124, or C125:
or a peptoid oligomer according to C103, C105, C106, C121, C122, C123, C124, or C125, and wherein the —NH 2 of each —CH 2 —CH 2 —CH 2 —NH 2 is replaced with —NMe 2 , —NHMe, or —NEt 2 ;
or a pharmaceutically acceptable salt, or solvate thereof or a stereoisomer, isotopic variant or tautomer thereof.
3. A peptoid oligomer according to formula IIIa:
wherein t is 2; one R 2 is 3-Me and the other R 2 is 5-Me; and R 1 is 2-aminoethyl, 3-aminopropyl, 2-(dimethylamino)ethyl, 2-(diethylamino)ethyl, 2-(methylamino)ethyl, 3-(dimethylamino)propyl, 3-(diethylamino)propyl, or 3-(methylamino)propyl;
or a pharmaceutically acceptable salt, or solvate thereof; or a stereoisomer, isotopic variant or tautomer thereof.
4. A peptoid oligomer according to formula IIIb, or IIIc:
wherein R 1 is 2-aminoethyl, 3-aminopropyl, 2-(dimethylamino)ethyl, 2-(diethylamino)ethyl, 2-(methylamino)ethyl, 3-(dimethylamino)propyl, 3-(diethylamino)propyl, or 3-(methylamino)propyl; t is 2; and one R 2 is 3-Me and the other R 2 is 5-Me;
or a pharmaceutically acceptable salt, or solvate thereof; or a stereoisomer, isotopic variant or tautomer thereof.
5. A peptoid oligomer:
or the peptoid oligomer wherein the —NH 2 of each —CH 2 —CH 2 —CH 2 —NH 2 or the —NH 2 of each —CH 2 —CH 2 —NH 2 is replaced with —NMe 2 , —NHMe, or —NEt 2 ;
or a pharmaceutically acceptable salt, or solvate thereof; or a stereoisomer, isotopic variant or tautomer thereof.
6. The peptoid oligomer according to
i) any one of claim 3 or 4 , wherein R 1 is
2-(dimethylamino)ethyl, 2-(diethylamino)ethyl, 2-(methylamino)ethyl, 3-(dimethylamino)propyl, 3-(diethylamino)propyl, or 3-(methylamino)propyl.
7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the peptoid oligomer of any one of claim 1 , 2 , or 3 .
8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the peptoid oligomer of any one of claim 4 or 5 .
9. A method for treating, ameliorating or managing a disease or condition that is or results from a bacterial infection, wherein the method comprises administering to a patient in need of such treatment, amelioration or management, a therapeutically effective amount of a peptoid oligomer of any one of claim 1 , 2 , 3 , 4 , or 5 , or a pharmaceutical composition thereof.
10. The method of claim 9 , wherein the disease or condition is or results from infection with gram positive or gram negative bacterial strains.
11. The method of claim 10 , wherein the disease or condition is or results from infection with Staphylococcus aureus.
12. The method of claim 10 , wherein the disease or condition is or results from infection with Methicillin-resistant Staphylococcus aureus (MRSA).